FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Recomp Stack

Fat Lossintermediate

87

シナジー

87
Share
ペプチド

3

平均日用量mcg

2,400

レベル

intermediate

追加

May 17, 2026

概要

The Recomp Stack targets simultaneous fat loss and muscle preservation through three complementary mechanisms. Tesamorelin, as an FDA-approved GHRH analog, stimulates endogenous GH production which shifts metabolism toward lipolysis and protein synthesis. Clinical trials specifically demonstrated Tesamorelin''s ability to reduce visceral adipose tissue (the metabolically dangerous deep abdominal fat) by 15-20% over 26 weeks without significant loss of lean mass — making it ideal for body recomposition rather than simple weight loss. AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) with a tyrosine addition. It retains the lipolytic (fat-burning) activity of GH without its growth-promoting or diabetogenic effects. AOD-9604 stimulates lipolysis and inhibits lipogenesis by mimicking the way natural GH regulates fat metabolism. Importantly, it does not affect blood sugar or promote cellular proliferation, making it safer for sustained fat-loss protocols. It received GRAS (Generally Recognized As Safe) status from the FDA for use as a food supplement, though injectable forms remain on the FDA Category 2 restricted-compounding list as of July 2026. CJC-1295 (no DAC) provides additional pulsatile GH stimulation that amplifies the Tesamorelin effect while maintaining physiological GH patterns. The triple combination creates a metabolic environment where the body preferentially burns fat while preserving and even building lean tissue — true recomposition. Results are optimized when combined with resistance training and moderate caloric deficit (200-300 calories below maintenance). Users should expect gradual rather than dramatic changes: 1-2 lbs of fat loss per week with stable or slightly increasing lean mass over 8-12 week cycles.

投与プロトコル

Tesamorelin

Every day· subcutaneous

Tesamorelinについて詳しく読む →

2,000 mcg

1回の投与あたり

AOD-9604

Every day· subcutaneous

AOD-9604について詳しく読む →

300 mcg

1回の投与あたり

CJC-1295 (no DAC)

Every day· subcutaneous

CJC-1295 (no DAC)について詳しく読む →

100 mcg

1回の投与あたり

目標と証拠

Fat lossMuscle preservationBody recompositionMetabolismVisceral fat
証拠ランク:人間臨床試験(RCT)

警告

  • Tesamorelin FDA-approved for different indication. AOD-9604 remains FDA Category 2 (restricted) as of July 2026. Results require caloric deficit and exercise.

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。